The Pharma Innovation Programme Singapore (PIPS) is an industry-led platform which aims to synergistically and strategically bring together public sector research capabilities and domain expertise of the pharmaceutical industry to enhance the productivity and operational efficiency within Singapore’s pharmaceutical sector through leveraging novel manufacturing technologies and data analytics.
Through this concerted effort spanning the public sector, industry partners, academia and government agencies, we will resolve pertinent issues to value-add to the sector and beyond. The current workstreams within PIPS include Biocatalysis, Continuous Manufacturing, Digital Factory, Particle Engineering and Plant Operations.
The consortium will continue to evolve according to the needs of the industry and align ourselves to be a focal point of excellence.
Visit the PIPS website for more information
Under the Research Collaboration Agreement (RCA) model, A*STAR and Collaborators will jointly develop and generate new Intellectual Property (IP). Project foreground IP (FIP) that is jointly developed will be jointly owned according to intellectual input. A*ccelerate Technologies, who is the commercialization arm for A*STAR, will assist with the arrangement of Licensing Agreement, if required.
Collaborators may choose to provide cash and/or in-kind contributions in the form of consumables, equipment, and manpower. A*STAR may also contribute in-kind contributions such as equipment and manpower, where the total contributions from A*STAR will be equivalent to the cost of the project contributed by the collaborators.
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders. Get inspired by our #WomeninSTEM